Dr G Baranidharan has been a Pain Medicine Consultant at the Leeds Teaching Hospitals NHS Trust, United Kingdom, since 2006. He is the clinical lead for Pain Medicine. He holds an appointment as an Honorary Clinical Associate Professor at the University of Leeds. Dr Baranidharan completed his MBBS from Madras Medical College (1996), Madras, India. He pursued his anaesthesia and Pain Medicine training at Yorkshire Deanery, UK and McMaster University, Canada (1999-2006). He has a Fellowship in Anaesthesia (FRCA) and Pain Medicine (FFPMRCA) from the Royal College of Anaesthesia and the Faculty of Pain Medicine. Dr Baranidharan developed the Neuromodulation Centre in Leeds from a small service to one of the most significant units in Europe. He is active in research and teaching. Most of his research activities are on Neuropathic pain and Neuromodulation. He has a particular interest in managing the pain of visceral origin. He has significantly contributed to developing a National Neuromodulation Registry for the United Kingdom and currently chairs the Data set Committee. Dr Baranidharan is the current Vice Dean of the Faculty of Pain Medicine, the Deputy Chair of the Board of Examiners and the Chair of the Professional Standards Committee and has contributed to various national initiatives. He has successfully run his annual cadaver workshop in Leeds since 2008 (www.paincourse.co.uk). Dr Baranidharan enjoys cycling, running, cricket and Badminton in his spare time.

Simon Bayerl practices in Berlin, Germany. His top areas of expertise are Spinal Stenosis, Familial Multiple Lipomatosis, Chronic Pain, Spinal Fusion, and Laminectomy. His clinical research consists of co-authoring 36 peer reviewed articles and participating in 2 clinical trials in the past 15 years.

I am interested in researching residual deficits in spinal cord injuries, which can be alleviated by improving efficacy of standard interventions and by developing newer techniques that harness the potential of surviving neuronal systems for recovery. My research also focuses on new insights into cellular and molecular mechanisms that restore neuronal function following SCI. Some of my latest studies include use of transcranial magnetic stimulation (TMS) and repetitive transcranial magnetic stimulation (rTMS); spinal cord diffusion tensor imaging (DTI), which provides a quantitative assessment of neural damage in various spinal cord pathologies; and other electroneurophysiological signals.

I am an associate research scientist at the Tim and Caroline Reynolds Center for Spinal Stimulation at the Kessler Foundation. During my PhD at the Toulouse Neuroimaging Center (ToNIC), my research focused on exploring appropriate measures and therapeutic interventions for the assessment and motor rehabilitation of individuals who had suffered a stroke. Now at Kessler Foundation, my research focuses on recovery from spinal cord injury by investigating the effects associated with the use of neuromodulatory interventions such as repetitive transcranial magnetic stimulation and spinal cord stimulation as adjunct therapies for neurorehabilitation.

I am an Academic Psychiatrist from the UK, with research interests in mood and anxiety disorders, and the treatment of these disorders with minimally invasive neuromodulation approaches. I also use electrophysiological and neuroimaging techniques to understand the mechanisms of action of these approaches. I recently led neuroimaging analyses for the BRIGhTMIND trial, the UK’s largest trial of transcranial magnetic stimulation (TMS) for treatment-resistant depression. I am currently developing approaches for boosting the effects of TMS by modifying the “brain state” at the time of stimulation. Key aspects of brain state include the excitability of the stimulated cortex, and active brain networks and connectivity pathways. By considering the brain state at the time of stimulation delivery, I seek to reduce the inter- and intra-individual variability characteristic of the effects of techniques such as TMS. My aim is to make well-tolerated, and popular, neuromodulation techniques more effective and more rapid for more people with difficult-to-treat mood and anxiety disorders.

Rostyslav Bubnov is working as a medical doctor in the clinical hospital ‘Pheophania’ of State Affairs Department, researcher in the Interferon Department of Zabolotny Institute of Microbiology and Virology, NAS of Ukraine, and corresponding member of Ukrainian Academy of Information. He is completing administrative responsibilities as National Representative of the European Association for Predictive, Preventive and Personalized Medicine (EPMA) in Ukraine. He received his MD in Horbachevsky Ternopil State Medical University (Ukraine) during the period of 1994-2000, and PhD in Kharkiv Medical Academy of Postgraduate Education during the period of 2009-2012. He studied medical law in International Solomon University (Kyiv) in 2013-2016. He has authored and co-authored over 100 peer-reviewed papers, 11 monographs, 20 UA patents (see http://scholar.google.com.ua/citations?user=k9YfXKwAAAAJ) and performs peer reviews and editorship for a number of journals (see https://publons.com/author/317326/rostyslav-v-bubnov) and served as expert evaluator for number of National and international projects. He is winner of number of award like President of Ukraine Award for young scientists 2012, Sentinels of Science award 2016 in Medicine, Top Reviewer 2019, etc.

Dr. Allen W. Burton is medical director of Abbott’s neuromodulation business, inclusive of Abbott’s neurostimulation and chronic pain management product portfolios. He is a board-certified anesthesiologist with an added certification in pain management and brings nearly 20 years of experience in patient care to Abbott, alongside a strong background leading large-scale clinical research programs.